Mads Agerbaek
Overview
Explore the profile of Mads Agerbaek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1678
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galsky M, Witjes J, Gschwend J, Milowsky M, Schenker M, Valderrama B, et al.
J Clin Oncol
. 2024 Oct;
43(1):15-21.
PMID: 39393026
JCO .CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection. The primary...
2.
Korner S, Tolbod L, Pedersen B, Boellaard T, Milling R, Brandt S, et al.
J Clin Med
. 2024 Aug;
13(16).
PMID: 39200797
Accurate assessment of therapy response to chemotherapy could possibly offer a bladder-sparing approach in selected patients with localized muscle-invasive bladder cancer (MIBC). The aim of this study was to evaluate...
3.
Holmsten K, Omland L, Als A, Agerbaek M, Dohn L, Lindberg H, et al.
Bladder Cancer
. 2024 Jul;
8(1):71-80.
PMID: 38994523
Background: Neoadjuvant cisplatin-based chemotherapy is standard care prior to radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). Objective: To assess efficacy and safety of two commonly used neoadjuvant schedules...
4.
Daugaard G, Lauritsen J, Bandak M, Agerbaek M, Als A, Dysager L, et al.
Eur Urol Focus
. 2024 Jun;
10(3):359-360.
PMID: 38871631
New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be...
5.
Nordentoft I, Lindskrog S, Birkenkamp-Demtroder K, Gonzalez S, Kuzman M, Levatic J, et al.
Eur Urol
. 2024 May;
86(4):301-311.
PMID: 38811314
Background And Objective: Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden...
6.
Wagner T, Toft B, Lauritsen J, Bandak M, Christensen I, Engvad B, et al.
Eur J Cancer
. 2024 Mar;
202:114025.
PMID: 38531266
Background: Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can...
7.
Korner S, Dreyer T, Carus A, Dohn L, Joensen U, Lam G, et al.
Scand J Urol
. 2024 Feb;
59:39-46.
PMID: 38406925
Objective: To investigate the impact of neoadjuvant chemotherapy implementation with gemcitabine-cisplatin on survival outcomes for patients with muscle-invasive bladder cancer in Denmark. Materials And Methods: Data were collected on all...
8.
Rosenvilde J, Lauritsen J, Bandak M, Wagner T, Agerbaek M, Dysager L, et al.
Eur Urol Oncol
. 2024 Jan;
7(3):589-596.
PMID: 38199869
Background And Objective: Optimal treatment outcomes in patients with metastatic nonseminoma testicular cancer are achieved with chemotherapy and subsequent surgery in cases with residual tumor. In Denmark, postchemotherapy retroperitoneal lumpectomy...
9.
Norgaard M, Mailhac A, Fagerlund K, Strunz-McKendry T, Agerbaek M, Jensen J
Acta Oncol
. 2023 Oct;
62(12):1784-1790.
PMID: 37787748
Background: Treatment patterns in locally advanced and metastatic urothelial bladder cancer (La/mUBC) is changing, but little is known about current treatment patterns, survival, and costs of these patients. Our aim...
10.
Lindskrog S, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4797-4807.
PMID: 37782315
Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full...